VONBURNÉ — RETENTION Program
The RETENTION Methodology — Northern Virginia

Your medication is working.
Your muscle is the
problem no one told you about.

GLP-1 medications are clinically proven to reduce weight. They are also clinically proven to take 25–40% of that weight from lean muscle mass — not fat. Left unaddressed, that loss is irreversible at the rate it occurs. VONBURNÉ's RETENTION program is the only structured resistance training methodology built specifically around this problem.

40%
of semaglutide
weight loss is muscle
20 yrs
of muscle loss
in 16 months
0
programs address
this specifically
The Problem

The drug is doing its job.
Your body is paying for it.

GLP-1 medications — Ozempic, Wegovy, Mounjaro, Zepbound — suppress appetite so effectively that most patients enter a sustained caloric deficit. That deficit reduces fat. It also accelerates the breakdown of skeletal muscle at a rate most physicians do not flag and most patients do not feel until the damage is significant.

Muscle loss reduces your resting metabolic rate. When you stop the medication, the weight returns as fat — not muscle. The net result is a body composition worse than where you started, not better.

The clinical literature identifies one primary intervention that changes this outcome: structured resistance training, specifically mapped to your drug phase.

40%
of total weight lost on semaglutide is lean muscle mass — not fat (STEP-1 Trial)
11%
average lean mass lost on tirzepatide over 72 weeks (SURMOUNT-1)
20 yrs
of normal age-related muscle loss compressed into 16 months of GLP-1 treatment. The loss rate exceeds what your body experiences across two full decades of aging. (Mechanick et al., Obesity Reviews, 2024)
The Solution

RETENTION.
Built around the drug — not despite it.

RETENTION is VONBURNÉ's proprietary resistance training methodology. It is not a general fitness program adapted for weight loss. It is a clinically grounded protocol designed around the specific physiological conditions created by GLP-1 receptor agonism — including dose escalation phases, energy availability constraints, and lean mass catabolism rates documented in peer-reviewed literature.

01
Phase 1 — Assessment
Baseline body composition, functional strength benchmarking, medication phase mapping, and individualized risk stratification before a single programming decision is made.
02
Phase 2 — Programming
Compound-primary resistance programming mapped to your GLP-1 escalation phase. Load, volume, and progression rules adjust with your drug cycle — not against it.
03
Phase 3 — Nutrition
General protein education and dietary framework guidance for a population under sustained appetite suppression. Coordinated with your physician and dietitian where applicable.
04
Phase 4 — Recovery
HRV-informed recovery protocols and active recovery structure mapped to training load and caloric availability — both of which fluctuate meaningfully on GLP-1 medications.
05
Phase 5 — Outcomes
Monthly biometric tracking against clinical benchmarks. You receive documented data on lean mass trends, strength progression, and program adherence — not anecdotal feedback.
The Clinical Foundation

This is not fitness
opinion.

RETENTION's programming parameters are derived from three peer-reviewed clinical sources: the STEP-1 trial DXA substudy documenting body composition changes under semaglutide, the SURMOUNT-1 DXA substudy documenting changes under tirzepatide, and the 2024 Mechanick et al. clinical consensus on strategies for minimizing muscle loss during incretin-mimetic drug therapy.

The resistance training evidence is equally direct. Multiple systematic reviews and meta-analyses confirm that resistance training is the primary evidence-based intervention for preserving lean mass during caloric restriction. Studies specifically examining GLP-1 combined with supervised exercise show attenuated weight regain after treatment cessation — meaning the training effect persists beyond the drug.

VONBURNÉ's RETENTION methodology is the applied translation of this literature into a structured, practitioner-executable protocol. Every programming decision cites a source. Nothing is general fitness approximation.

Key clinical benchmarks — RETENTION measures against these
6.92kg
Average lean mass lost on semaglutide over 68 weeks without resistance intervention. This is RETENTION's primary outcome target.
10.9%
Average lean mass lost on tirzepatide over 72 weeks. Consistent across all dose levels and age groups.
3–5%/decade
Normal aging-related muscle loss rate. GLP-1 medication compresses 20 years of this loss into 16 months.
Sources: Wilding et al. (STEP-1) | Look et al. 2025 (SURMOUNT-1) | Mechanick et al., Obesity Reviews, 2024
Who This Is For

RETENTION is selective
by design.

This is built for you if
You are currently on a GLP-1 medication and are not doing structured resistance training
You are 35–65, a professional, and treat your body as a performance asset
You want documented outcomes — not motivational coaching
You are based in Northern Virginia or the D.C. metro area
You will train with consistency if the program is built correctly for your situation
This is not the right fit if
You are not on a GLP-1 medication and have no plan to begin one
You are looking for motivation, accountability check-ins, or general wellness programming
You want a physique-focused program with no concern for lean mass preservation
You are not prepared to train a minimum of 3 sessions per week
The Process

From inquiry to
first session — five steps.

01
Submit Inquiry
Complete the brief form below. Name, contact, and GLP-1 status. Takes 90 seconds.
→
02
Confirmation Call
A 10-minute call within 24 hours to confirm fit, answer questions, and set expectations.
→
03
Documents Sent
Program agreement, intake form, and onboarding documents delivered digitally for signature.
→
04
Program Begins
Payment confirmed. Phase 1 assessment scheduled within 72 hours. First session follows.
→
05
Monthly Tracking
Biometric data collected every 4 weeks. Outcome report delivered. Program adjusted to your progression.
Begin the Program

Your medication is losing
muscle every week.
This is how you stop it.

Submitting this form takes 90 seconds. It is not a commitment — it initiates a brief conversation to confirm the program is the right fit for your specific situation and medication status.

Following the conversation, you will receive the program onboarding documents digitally. No payment is collected until documents are reviewed and signed.

VONBURNÉ accepts a limited number of clients per month to maintain the documented outcome standard the RETENTION methodology requires. If capacity is currently full you will be notified and placed on a priority list.

RETENTION Program Inquiry
Northern Virginia — Limited Availability
I understand this form initiates a brief qualification conversation — not a payment or commitment. I confirm I am at least 18 years of age and located in the Northern Virginia / D.C. metro area. No payment is collected at this stage.

Your information is not sold or shared. VONBURNÉ will contact you within 24 hours of submission.

✦
Inquiry Received

Your inquiry has been submitted. VONBURNÉ will contact you within 24 hours to schedule your brief qualification conversation.

Check your email for a confirmation. If you do not receive one within a few minutes, check your spam folder or contact directly through the site.

VONBURNÉ
The RETENTION Methodology
Virginia LLC  ·  Northern Virginia  ·  vonburne.com